Journal of Parasitic Diseases: Diagnosis and Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Perspective - Journal of Parasitic Diseases: Diagnosis and Therapy (2025) Volume 10, Issue 3

Parasitic Infection Treatment: Evolving Strategies and Future Directions

Michael Thompson*

Institute of Tropical Medicine, University of Liverpool, United Kingdom

Corresponding Author:
Michael Thompson
Institute of Tropical Medicine,
University of Liverpool,
United Kingdom
E-mail: m.thompson@liv.ac.uk

Received: 02-Aug-2025, Manuscript No. AAPDDT-25-166521; Editor assigned: 03-Aug-2025, AAPDDT-25-166521 (PQ); Reviewed: 17-Aug-2025, QC No. AAPDDT-25-166521; Revised: 22-Aug-2025, Manuscript No. AAPDDT-25-166521 (R); Published: 30-Aug-2025, DOI:10.35841/2591-7846.10.3.227

Citation: Thompson M. Parasitic infection treatment: evolving strategies and future directions, J Parasit Dis Diagn Ther. 2025; 10(3):227

Introduction

Introduction Parasitic infections remain a major global health concern, especially in low- and middle-income countries. Despite considerable progress in diagnostics and therapeutics, the management of parasitic diseases continues to face significant challenges, including drug resistance, limited access to healthcare, and inadequate vaccine development. This perspective article highlights current treatment modalities for parasitic infections, evaluates therapeutic gaps [1, 2, 3, 4].

Explores promising advances in drug development, personalized medicine, and immunotherapeutic strategies that may redefine future treatment paradigms. Parasitic infections caused by protozoa, helminths, and ectoparasites impact billions globally, with diseases such as malaria, schistosomiasis, leishmaniasis, and filariasis leading to high morbidity and mortality. Traditional treatment regimens have relied heavily on chemotherapeutic agents; however, increasing reports of drug resistance, adverse side effects, and lack of broad-spectrum activity have necessitated the search for innovative solutions. A holistic and integrative approach to treatment incorporating pharmacological, immunological, and molecular interventions—is now more critical than ever [5, 6].

Antiprotozoal drugs: e.g., Artemisinin for malaria, Amphotericin B for leishmaniasis, and Metronidazole for giardiasis. Anthelmintic agents: e.g., Albendazole, Mebendazole, and Ivermectin for helminthic infections. Combination therapies: Used increasingly to combat resistance, such as artemisinin-based combination therapies (ACTs) for malaria. Despite these treatments, challenges persist regarding efficacy, tolerability, and availability, especially in resource-limited settings. Challenges in Treatment: Drug Resistance: Resistance to frontline drugs, particularly in malaria and leishmaniasis, threatens treatment efficacy. Toxicity and Side Effects: Many antiparasitic drugs have a narrow therapeutic window, leading to complications. Lack of Universal Drugs: No single drug offers pan-parasitic activity, necessitating disease-specific regimens. Healthcare Access: In endemic regions, logistical and financial barriers hinder timely and adequate treatment. Innovations and Future Directions: Novel Drug Development New targets in parasite metabolism and replication are being explored to develop next-generation antiparasitics with fewer side effects and reduced resistance potential. Host-Directed Therapies Modulating host immune responses and targeting host-parasite interactions offer a novel therapeutic frontier, especially for chronic or relapsing infections. Vaccine Development Although still underdeveloped, vaccines for malaria (e.g., RTS,S/AS01) and other parasitic diseases represent significant progress in preventive treatment strategies. Nanotechnology and Drug Delivery Systems Nanocarriers and lipid-based formulations improve drug solubility, target specificity, and sustained release, reducing toxicity and enhancing therapeutic outcomes. Genomic and Precision Medicine Advances in genomics may enable tailored treatment strategies based on host genetics and parasite genotypes, ensuring better response rates and reduced adverse effects. Integrated Disease Management Combining treatment with preventive measures—such as vector control, sanitation, and education—offers a sustainable strategy to reduce disease burden. Current Therapeutic Strategies: Treatment of parasitic diseases has traditionally focused on mono- or combination drug therapies, often species-specific. Some of the commonly used therapies include [7, 8, 9, 10].

Conclusion

The treatment of parasitic infections is at a critical juncture, balancing the legacy of effective but limited therapies with the promise of innovative and integrative solutions. Addressing current challenges through a multidisciplinary lens—encompassing molecular biology, immunology, pharmacology, and public health—will be essential for developing more effective, accessible, and sustainable treatment options. As research advances, global collaboration and equitable access will be vital in translating innovation into impact.

References

  1. Branch-Elliman W, Elwy AR, Chambers DA. Embracing dynamic public health policy impacts in infectious diseases responses: leveraging implementation science to improve practice. Front Public Health. 2023;11:1207679.

    2. Indexed at, Google Scholar, Cross Ref

  2. Shih FY, Lyu SY, Yang CC, et al. Public Fear and Risk Perception During Dengue Fever Outbreak in Taiwan. Asia Pac J Public Health. 2023;35(8):502-9.

    3. Indexed at, Google Scholar, Cross Ref

  3. Oleribe O, Ezechi O, Osita-Oleribe P, et al. Public perception of COVID-19 management and response in Nigeria: a cross-sectional survey. BMJ Open. 2020;10(10):e041936.

    4. Indexed at, Google Scholar, Cross Ref

  4. de Vries M, Claassen L, Te Wierik MJ, et al. Dynamics in public perceptions and media coverage during an ongoing outbreak of meningococcal W disease in the Netherlands. BMC Public Health. 2022;22(1):633.

    5. Indexed at, Google Scholar, Cross Ref

  5. Abrams EM, Greenhawt M. Risk communication during COVID-19. J Allergy Clin Immunol Pract. 2020;8(6):1791-4.

    6. Indexed at, Google Scholar, Cross Ref

  6. Li Y, Wu X, Wang J. Netizens’ risk perception in new coronary pneumonia public health events: an analysis of spatiotemporal distribution and influencing factors. BMC Public Health. 2022;22(1):1445.

    7. Indexed at, Google Scholar, Cross Ref

  7. Park JY, Lee K, Chung DR. Public interest in the digital transformation accelerated by the COVID-19 pandemic and perception of its future impact. Korean J Intern Med. 2022;37(6):1223.

    8. Indexed at, Google Scholar, Cross Ref

  8. Pignocchino G, Di Baldassarre G, Mondino E, et al. Public risk perception of air pollution in the general population of Italy and Sweden during the COVID-19 pandemic: Environmental and socio-demographic drivers. Prev Med. 2023;173:107601.

    9. Indexed at, Google Scholar, Cross Ref

  9. Nwagbara UI, Osual EC, Chireshe R, et al. Knowledge, attitude, perception, and preventative practices towards COVID-19 in sub-Saharan Africa: A scoping review. PLoS One. 2021;16(4):e0249853.

    10. Indexed at, Google Scholar, Cross Ref

  10. Abu Hatab A, Krautscheid L, Amuakwa-Mensah F. COVID-19 risk perception and public compliance with preventive measures: Evidence from a multi-wave household survey in the MENA region. PLoS One. 2023;18(7):e0283412.

    11. Indexed at, Google Scholar, Cross Ref

Get the App